Compare ANAB & PRGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANAB | PRGO |
|---|---|---|
| Founded | 2005 | 1887 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.6B |
| IPO Year | 2015 | 2013 |
| Metric | ANAB | PRGO |
|---|---|---|
| Price | $51.10 | $10.76 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 3 |
| Target Price | ★ $71.67 | $19.33 |
| AVG Volume (30 Days) | 542.3K | ★ 2.4M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 10.28% |
| EPS Growth | ★ 91.02 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $234,603,000.00 | $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $52.14 | $1.02 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $17.11 | $9.23 |
| 52 Week High | $73.30 | $28.44 |
| Indicator | ANAB | PRGO |
|---|---|---|
| Relative Strength Index (RSI) | 31.21 | 45.86 |
| Support Level | $43.75 | $10.46 |
| Resistance Level | $51.67 | $12.36 |
| Average True Range (ATR) | 2.68 | 0.45 |
| MACD | -0.99 | -0.04 |
| Stochastic Oscillator | 5.47 | 41.24 |
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.